Are you Feng Xu?

Claim your profile

Publications (2)6.44 Total impact

  • Article: Application of near-infrared dyes for tumor imaging, photothermal, and photodynamic therapies.
    [show abstract] [hide abstract]
    ABSTRACT: Near-infrared (NIR) dyes, small organic molecules that function in the NIR region, have received increasing attention in recent years as diagnostic and therapeutic agents in the field of tumor research. They have been demonstrated great successes in imaging and treating tumors both in vitro and in vivo. And their different applications in clinical practices have made rapid gains. This review primarily focuses on the progress of the application of NIR dyes in tumor imaging and therapy. In particular, advances in the use of different NIR dyes in tumor-specific imaging, photothermal, and photodynamic therapies are discussed. Limitations and prospects associated with NIR dyes in diagnostic and therapeutic application are also reviewed. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
    Journal of Pharmaceutical Sciences 11/2012; · 3.06 Impact Factor
  • Article: Local gene delivery for cancer therapy.
    [show abstract] [hide abstract]
    ABSTRACT: Gene therapy is an emerging technique with widespread applications in treatment of cardiovascular diseases, monogenic disorder, infectious diseases, and especially cancers. The major challenge for gene therapy is to deliver therapeutic genes to target tissues. Although various gene delivery vectors such as harmless viruses and micro/nano-particles have been developed (i.e. commonly system delivery), concerns remain for the transfection efficiency and stability of those working copies in these vectors. Local gene delivery such as intratumoral infusion, electroporation and implants offers significantly enhanced transfection efficiency with decreased toxicity compared to system delivery and has been broadly used in clinics. In this paper, we reviewed the local gene delivery methods and discussed their distinctive advantages and potential challenges in cancer treatment.
    Current Gene Therapy 06/2011; 11(5):423-32. · 3.39 Impact Factor